India Diabetes Care Devices Market Overview, 2031

Key Insights

• According to the research report, "India Diabetes Care Devices Market Outlook, 2031," published by Bonafide Research, the India Diabetes Care Devices Market is anticipated to add to more than 1.26 Billion by 2026-31.
• The Indian diabetes care devices market is undergoing a rapid transition from imported, high-cost equipment to domestically developed continuous biosensors and smart digital platforms. While multinational corporations historically dominated the market, Indian medtech startups such as Ultrahuman (M1 biosensor), HealthifyMe, and BeatO (Health Arx Technologies) have introduced affordable, smartphone-integrated Continuous Glucose Monitoring (CGM) systems and smart glucometers tailored for the price-sensitive Indian consumer. A key technological breakthrough is the integration of metabolic health tracking with AI-driven dietary engines.
• Traditional finger-stick self-monitoring blood glucose (SMBG) devices remain the volume backbone of the market, but continuous monitoring wearables are experiencing accelerated adoption in urban Tier-1 and Tier-2 centers. Regulatory approvals by the Central Drugs Standard Control Organization (CDSCO) for factory-calibrated CGMs including Abbott's FreeStyle Libre portfolio and Medtronic's MiniMed 780G closed-loop automated insulin delivery systems have enabled endocrinologists to transition intensive insulin users toward continuous data tracking.
• According to comprehensive epidemiological data from the ICMR-INDIAB study and the International Diabetes Federation (IDF), over 101 million adults in India are living with diabetes, while an estimated 136 million individuals present with prediabetes. India carries the second-highest diabetic population globally, with an age-standardized adult prevalence rate of approximately 10.5%. Crucially, over 43% of affected adults representing more than 38.5 million people remain formally undiagnosed. Type 1 diabetes affects over 940,000 individuals across all age brackets in India, including more than 300,000 children and adolescents under age 20.

Market Outlook

• Major e-pharmacy platforms (such as Tata 1mg, Apollo 24/7, PharmEasy, and Netmeds) serve as primary sales channels for over-the-counter glucometers, SMBG test strips, insulin pens, and continuous biosensors, bypassing traditional hospital procurement bottlenecks. Concurrently, non-profit initiatives and public-private partnerships under the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) are expanding basic screening equipment into Primary Health Centres (PHCs) and Ayushman Arogya Mandirs. Future growth will rely on low-cost, needle-free optical/RF glucose sensors, smartphone-enabled dongles, and cloud-connected telemetry platforms that allow primary care doctors to remotely monitor diabetic patients across rural and semi-urban geographies.
• While consumer demand is expanding, device manufacturers face regulatory standardization under the Medical Devices Rules (MDR) enforced by the Central Drugs Standard Control Organization (CDSCO), which requires mandatory registration, local clinical evaluations, and stringent QMS standards for imported and domestic hardware. Furthermore, government procurement under the Public Procurement (Preference to Make in India) Order is favoring local manufacturers for public tender allocations in government hospital networks. Key regulatory standards, clinical protocols, and research frameworks are guided by the Central Drugs Standard Control Organization (CDSCO), the Indian Council of Medical Research (ICMR), the Research Society for the Study of Diabetes in India (RSSDI), and Diabetes India. Leading commercial and domestic medtech companies actively driving the Indian commercial space include Abbott Laboratories India, Roche Diabetes Care India, Medtronic India, Dexcom, BeatO (Health Arx Technologies), Ultrahuman Healthcare, HealthifyMe, Ascensia Diabetes Care India, and Agappe Diagnostics.

Market Dynamics

Driver: Critical disease prevalence, expanding middle class, and e-commerce accessibility
The primary growth driver for the Indian diabetes care devices market is the country's staggering epidemic-scale disease burden combined with an expanding middle class and digitized distribution channels. According to landmark epidemiological studies by the Indian Council of Medical Research (ICMR-INDIAB), India is home to over 101 million adults living with diabetes and an additional 136 million individuals with prediabetes. As urban lifestyle changes accelerate insulin resistance, there is a rapidly growing pool of tech-savvy, middle-class consumers who possess higher disposable incomes and a strong willingness to invest out-of-pocket in personal health technology.
Challenge: High out-of-pocket expenditure, price sensitivity, and lack of public reimbursement
Despite high clinical demand, market penetration for advanced diabetes technologies in India is heavily constrained by extreme price sensitivity and the lack of comprehensive public or private insurance coverage. Unlike Western markets where continuous glucose monitors (CGMs) and automated insulin pumps are fully subsidized by statutory health insurance or national health programs, over 60% of total healthcare expenditure in India is paid directly out-of-pocket by patients.
Trend: Rise of domestic health-tech startups, AI dietary localizations, and DTC biosensing
A defining trend transforming the Indian diabetes care market is the emergence of innovative domestic health-tech companies that combine direct-to-consumer (DTC) continuous biosensor hardware with localized artificial intelligence (AI) software. Platforms developed by Indian medtech startups such as Ultrahuman, BeatO, and HealthifyMe are disrupting traditional distribution models by bundling Continuous Glucose Monitors (CGMs) and smart glucometers with AI-driven mobile apps. These platforms specifically decode South Asian dietary habits, evaluating how carbohydrate-heavy local meals impact glycemic variability and time-in-range (TIR) metrics.

Segment Analysis

India Diabetes Care Devices By Product Type
• India’s blood glucose monitoring systems market is strongly influenced by affordability, accessibility, and the recurring cost of consumables. Conventional glucometers and test strips remain practical choices for many households, particularly where patients prefer familiar testing routines and readily available supplies. Continuous glucose monitoring systems offer a different value proposition by revealing glucose fluctuations associated with meals, exercise, sleep, and medication. A distinctive opportunity lies in developing affordable sensors, locally understandable mobile applications, and devices that work reliably across different levels of digital literacy. Manufacturers can also differentiate themselves through accessible after-sales support, dependable strip availability, and distribution through pharmacies and online channels.
• India’s insulin delivery devices market reflects the need to balance treatment precision with affordability and ease of use. Insulin syringes and pens remain relevant for patients who prioritize accessible, familiar administration methods, while insulin pumps and connected delivery technologies offer more individualized treatment management. The recurring cost of needles, cartridges, and infusion supplies can influence long-term adoption, making consumable availability a key commercial consideration. Local manufacturing, simplified device maintenance, and patient education in regional languages can help manufacturers address practical barriers. Another opportunity lies in making advanced delivery systems easier to use for children, working adults, and older patients who need insulin administration to fit around everyday responsibilities.



India Diabetes Care Devices By Disease Type
• India’s type 1 diabetes segment requires devices that support uninterrupted insulin therapy and frequent glucose assessment throughout daily life. Continuous glucose monitoring, insulin pumps, smart pens, and integrated automated insulin delivery technologies are particularly relevant because they can help users respond to changing glucose patterns and manage treatment more systematically. However, adoption depends on more than device functionality: training, access to specialist care, replacement supplies, and the ability to manage devices in schools, workplaces, and smaller cities all matter. Manufacturers can address these needs through pediatric-friendly designs, discreet wearables, accessible technical support, and locally adapted education programs for patients and caregivers.
• India’s type 2 diabetes segment is shaped by diverse patient needs, ranging from individuals managing their condition through lifestyle changes and oral medication to those requiring insulin and more intensive monitoring. This creates demand for flexible device options rather than a single technology suited to everyone. Affordable glucometers and widely available strips remain important for routine monitoring, while continuous glucose monitoring can offer useful insights for selected patients whose treatment requires closer assessment of glucose patterns. A distinctive opportunity is to connect device use with dietary counseling, physical activity guidance, and clinician follow-up without making diabetes management unnecessarily complicated. Simple interfaces, convenient consumable replenishment, and actionable reporting can help support consistent long-term engagement.

India Diabetes Care Devices By End User
• India’s home and self-care segment depends on devices that are affordable, easy to operate, and supported by accessible replacement supplies. Patients often manage diabetes alongside work, family responsibilities, and travel, making portable meters, convenient testing kits, and wearable glucose sensors valuable when they fit individual treatment needs. Digital health applications and remote consultations create opportunities to share readings with clinicians, but their usefulness depends on clear explanations and manageable technology requirements. Regional-language instructions, caregiver-friendly interfaces, reliable customer support, and flexible purchasing options can distinguish successful products.
• India’s hospitals are important settings for diabetes assessment, treatment initiation, insulin management, and patient education. They require monitoring devices that are reliable in busy clinical environments, straightforward for staff to operate, and compatible with infection-prevention procedures. Hospitals also influence the adoption of home-use devices because clinicians frequently guide patients on selecting meters, sensors, and insulin-delivery systems. Affordability and the availability of consumables after discharge can affect whether patients continue using the recommended technology.
• India’s diagnostic centers serve patients who need glucose testing for initial assessment, routine follow-up, or further evaluation recommended by healthcare professionals. Their priorities include consistent measurement procedures, quality control, dependable equipment, and efficient patient processing. The needs of large diagnostic chains may differ from those of smaller independent laboratories, particularly in purchasing, maintenance, and technology integration. Device suppliers can differentiate themselves through reliable service support, staff training, and streamlined reporting. Another opportunity is to improve the connection between diagnostic results and subsequent diabetes management by making reports easier for clinicians and patients to interpret.
• India’s ambulatory surgical centers need diabetes care devices that support appropriate glucose assessment before, during, and after outpatient procedures, according to clinical requirements. Their priorities include rapid access to readings, reliable performance, hygienic handling, and efficient documentation. Patients may arrive with their own glucose meters, continuous glucose monitors, insulin pens, or pumps, so clinical teams need clear procedures for reviewing existing treatment and managing devices around surgery. Opportunities exist for compact monitoring equipment, staff education, and standardized workflows that help coordinate surgical care with diabetes management.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Diabetes Care Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Blood Glucose Monitoring Systems
• Insulin Delivery Devices

By Disease Type
• Type 1 Diabetes
• Type 2 Diabetes

By End User
• Home/Self-Care
• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers